ideasIdea
GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer
Coaching-based weight loss did not clearly cut breast cancer recurrence in BWEL, perhaps because the weight loss was too small. Drugs that produce three times as much weight loss could settle whether weight itself matters.
BWEL achieved modest weight loss with no clear iDFS effect. Bariatric surgery cohorts, with 25-30% weight loss, show large reductions in hormone-related cancers. GLP-1 receptor agonists sit between the two and are already widely used by breast cancer survivors off-trial; a randomised trial would answer the biological question BWEL could not and define safety alongside endocrine therapy (lean mass loss, bone density, gastrointestinal effects with CDK4/6 inhibitors).
Hypothesis
In women with stage II-III HR-positive breast cancer and BMI at least 30 on adjuvant endocrine therapy, two years of semaglutide or tirzepatide with resistance exercise improves invasive disease-free survival compared with lifestyle counselling alone, with the effect mediated by weight loss and reduced insulin and oestradiol.
Rationale
Obesity is associated with about 30% higher breast cancer mortality and with reduced aromatase inhibitor efficacy; GLP-1 receptor agonists produce sustained 15-20% weight loss; observational data suggest lower obesity-related cancer incidence. The exercise component protects lean mass, which rapid weight loss otherwise depletes.
What would test it
Phase 3 placebo-controlled trial (about 3,000 women) with iDFS primary endpoint, body composition by DXA, bone density and patient-reported outcomes; pre-specified mediation analysis by percentage weight loss. An industry-academic partnership is realistic given the commercial value of a cancer label.
Maturity
speculative
Who has to act
industry
Cost to try
Large (over $50M)
Years to first evidence
8
Bottlenecks it attacks
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.